While preclinical data support the potential of lipophagy modulators such as metformin, quercetin, and PLIN2 inhibitors, clinical application remains hindered by HCC heterogeneity, stage-dependent efficacy variations, and drug delivery constraints. The gene discussed is PLIN2; the disease is hepatocellular carcinoma.